Abcam, ab257620, Human PTRF knockout HeLa cell lysate

Size: 1Kit
CAVIN1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 191 bp insertion in exon1 and 5 bp deletion in exon1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 191 bp insertion in exon1 and 5 bp deletion in exon1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-CAVIN1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PTRF also known as Cavin-1 is a protein with a mass of approximately 43 kDa. It functions primarily as a regulator of caveolae formation and stability. Caveolae are small flask-shaped invaginations in the plasma membrane. PTRF interacts directly with caveolin proteins to facilitate caveolae assembly. It is largely expressed in adipose tissue muscle tissue and endothelial cells indicating a significant role in cellular processes in these cells.
Biological function summary
PTRF facilitates various processes like signal transduction and lipid metabolism due to its role in caveolae function. As part of the caveolae complex it is essential for maintaining structural integrity and organization. PTRF interacts with other proteins such as cavin family members and caveolins aiding in cellular response to mechanochemical stimuli. By regulating the caveolae PTRF influences activities including endocytosis and potocytosis.
Pathways
PTRF is critical in cholesterol homeostasis and endothelial nitric oxide synthase (eNOS) signaling pathways. It associates with caveolin-1 modulating these pathways to balance lipid composition and promote endothelial function. The interaction between PTRF and caveolin-1 enhances nitric oxide production which is important for vascular tone regulation and cellular stress response. This positions PTRF as a regulator in cardiovascular and metabolic pathways.
Defects or deficiencies in PTRF can lead to disorders such as lipodystrophy and muscular dystrophy. The absence or malfunction of PTRF disrupts normal caveolae structure leading to impaired lipid storage and muscle function. PTRF's interaction with caveolin-1 connects it to cardiovascular diseases as caveolin-1 mutations contribute to the pathogenesis of cardiac dysfunction. Understanding PTRF's role offers insights into therapeutic strategies for these conditions.